MX2009012832A - Inhibidor de pirazolopirimidinona quinasa. - Google Patents

Inhibidor de pirazolopirimidinona quinasa.

Info

Publication number
MX2009012832A
MX2009012832A MX2009012832A MX2009012832A MX2009012832A MX 2009012832 A MX2009012832 A MX 2009012832A MX 2009012832 A MX2009012832 A MX 2009012832A MX 2009012832 A MX2009012832 A MX 2009012832A MX 2009012832 A MX2009012832 A MX 2009012832A
Authority
MX
Mexico
Prior art keywords
kinase inhibitor
pyrazolopyrimidinone
pyrimidin
compound
pyrazolo
Prior art date
Application number
MX2009012832A
Other languages
English (en)
Spanish (es)
Inventor
Arthur F Kluge
Original Assignee
Agennix Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agennix Ag filed Critical Agennix Ag
Publication of MX2009012832A publication Critical patent/MX2009012832A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MX2009012832A 2007-05-29 2008-05-28 Inhibidor de pirazolopirimidinona quinasa. MX2009012832A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US93215507P 2007-05-29 2007-05-29
EP07113226A EP2019101A1 (en) 2007-07-26 2007-07-26 Pyrazol[3,4-d]pyrimidin-4-one useful as Kinase Inhibitor
PCT/EP2008/056569 WO2008145678A1 (en) 2007-05-29 2008-05-28 Pyrazolopyrimidinone kinase inhibitor

Publications (1)

Publication Number Publication Date
MX2009012832A true MX2009012832A (es) 2010-05-17

Family

ID=38556321

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009012832A MX2009012832A (es) 2007-05-29 2008-05-28 Inhibidor de pirazolopirimidinona quinasa.

Country Status (19)

Country Link
US (2) US8304418B2 (enExample)
EP (2) EP2019101A1 (enExample)
JP (1) JP2010528088A (enExample)
KR (1) KR20100040806A (enExample)
CN (1) CN101765600A (enExample)
AR (1) AR066737A1 (enExample)
AT (1) ATE522533T1 (enExample)
AU (1) AU2008257534A1 (enExample)
CA (1) CA2689090A1 (enExample)
DK (1) DK2170891T3 (enExample)
EA (1) EA200901536A1 (enExample)
ES (1) ES2370677T3 (enExample)
HR (1) HRP20110768T1 (enExample)
IL (1) IL202375A0 (enExample)
MX (1) MX2009012832A (enExample)
SI (1) SI2170891T1 (enExample)
TW (1) TW200906831A (enExample)
WO (1) WO2008145678A1 (enExample)
ZA (1) ZA200908943B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102428086B (zh) * 2009-04-29 2014-08-20 内尔维阿诺医学科学有限公司 Cdk抑制剂的盐类
WO2013059634A1 (en) 2011-10-20 2013-04-25 The Regents Of The University Of California Use of cdk9 inhibitors to reduce cartilage degradation
WO2015172713A1 (zh) * 2014-05-13 2015-11-19 广东东阳光药业有限公司 一种中间体的制备方法
EP3206749B1 (en) 2014-10-14 2021-09-08 The Regents of the University of California The cdk9 and brd4 inhibitors flavopiridol and jq1 to inhibit cartilage inflammation

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) * 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US3916889A (en) * 1973-09-28 1975-11-04 Sandoz Ag Patient ventilator apparatus
US4008719A (en) * 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4710384A (en) * 1986-07-28 1987-12-01 Avner Rotman Sustained release tablets made from microcapsules
EG18377A (en) * 1986-09-19 1993-04-30 Lilly Co Eli Process for preparing glycopeptide antibiotics
US5073543A (en) * 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) * 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) * 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) * 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
RU2139731C1 (ru) * 1992-11-13 1999-10-20 Айдек Фармасьютикалс Корпорейшн (US Способ лечения, антитела, гибридома
US5591767A (en) * 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it) * 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US6531477B1 (en) * 1998-10-13 2003-03-11 Dupont Pharmaceuticals Company 6-substituted pyrazolo [3,4-d] pyrimidin-4-ones useful as cyclin dependent kinase inhibitors
US6559152B2 (en) * 1998-10-13 2003-05-06 Dupont Pharmaceuticals Company 6-substituted pyrazolo[3,4-d]pyrimidin-4-ones useful as cyclin dependent kinase inhibitors
ATE365749T1 (de) 2000-05-12 2007-07-15 Gpc Biotech Ag Humane peptide/proteine, die das töten von zellen,einschliesslich lymphoide tumorzellen, herbeiführen oder bewirken
IT1317975B1 (it) 2000-06-16 2003-07-21 Christian Pio Pedulla Presa multipla volante.
US20040248905A1 (en) * 2001-07-10 2004-12-09 Markwalder Jay A 6-Substituted pyrazolo [3,4-d] pyrimidin-4-ones useful as cyclin dependent kinase inhibitors
PL369742A1 (en) * 2001-10-15 2005-05-02 Gpc Biotech Inc. Inhibitors of cyclin-dependent kinases, compositions and uses related thereto
JP5064795B2 (ja) * 2003-04-07 2012-10-31 アジェニックス ユーエスエー インク． サイクリン依存性キナーゼの阻害剤、組成物及びそれに関連する使用
EP1678147B1 (en) 2003-09-15 2012-08-08 Lead Discovery Center GmbH Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases
BRPI0418095A (pt) 2003-12-23 2007-04-17 Gpc Biotech Inc inibidores de quinases dependentes de ciclina, composições e usos relacionados aos mesmos

Also Published As

Publication number Publication date
EP2019101A1 (en) 2009-01-28
IL202375A0 (en) 2010-06-30
US8304418B2 (en) 2012-11-06
US20130035349A1 (en) 2013-02-07
HRP20110768T1 (hr) 2011-11-30
DK2170891T3 (da) 2011-12-12
CA2689090A1 (en) 2008-12-04
WO2008145678A1 (en) 2008-12-04
TW200906831A (en) 2009-02-16
AU2008257534A1 (en) 2008-12-04
ATE522533T1 (de) 2011-09-15
AR066737A1 (es) 2009-09-09
EA200901536A1 (ru) 2010-06-30
JP2010528088A (ja) 2010-08-19
KR20100040806A (ko) 2010-04-21
CN101765600A (zh) 2010-06-30
SI2170891T1 (sl) 2011-12-30
ZA200908943B (en) 2010-08-25
US20100160350A1 (en) 2010-06-24
EP2170891A1 (en) 2010-04-07
ES2370677T3 (es) 2011-12-21
EP2170891B1 (en) 2011-08-31

Similar Documents

Publication Publication Date Title
WO2006069080A3 (en) Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2m3-b]pyrimidin-4-yl-amines as janus kinase inhibitors
EP1945222A4 (en) PYRROLO [2,1-F] [1,2,4] TRIAZIN-4-YLAMINE DERIVATIVES INHIBITORS OF IGF-1R KINASE FOR THE TREATMENT OF CANCER AND OTHER HYPERPROLIFERATIVE DISEASES
EP4606378A3 (en) Salts of the janus kinase inhibitor (r)-3-( 4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3- cyclopentylprop anenitrile
MY146474A (en) Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
TW200745123A (en) Pyrazolopyrimidines as protein kinase inhibitors
ZA200802998B (en) Use of pyrazolo [1,5-a] pyrimidine derivatives for inhibiting protein kinases methods for inhibiting protein kinases
TW200745128A (en) Pyrazolopyrimidines as protein kinase inhibitors
AP2010005346A0 (en) 3H-[1,2,3]triazolo[4,5-D]pyrimidine compounds, their use as mTOR kinase and P13 kinase inhibitors, and their synthesis.
TW200728275A (en) Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
IL176737A0 (en) Pyrazolo[1,5-a] pyrimidin-7-yl-amine derivatives for use in the treatment of protein kinase dependent diseases
CL2008001364A1 (es) Uso de compuestos derivados de imidazol(1,2-b) piridazina y pirazolo(1,5-a) pirimidina inhibidores de tirosina quinasa pi-para tratar tumor benigno o maligno, entre otros; compuestos dereivados de imidazol(1,2-b)piridazina y pirazolo(1,5-a)pirimidina; composiciones farmaceuticas; y metodo de preparacion de compuestos.
GEP20115283B (en) Pyrrolopyrimidine compounds and their uses
TW200745127A (en) Pyrazolopyrimidines as protein kinase inhibitors
WO2006124354A3 (en) Tyrosine kinase inhibitors
PL1758871T3 (pl) Pirazolopirymidyny
PL2188289T3 (pl) (7H-pirolo[2,3-D]pirymidyn-4-ylo)-piperazyny jako inhibitory kinaz do leczenia nowotworów i zapalenia
CY1110666T1 (el) Πυραζολοπυριμιδινες καταλληλες για θεραπεια καρκινικων νοσων
MX2009012832A (es) Inhibidor de pirazolopirimidinona quinasa.
TW200628156A (en) Combination of a SRC kinase inhibitor and a BCR-ABL inhibitor for the treatment of proliferative diseases
WO2007109093A3 (en) Pyrazolo[1,5-a]pyrimidine derivatives and methods of use thereof
WO2006039582A3 (en) Compositions and methods for diagnosing and treating brain cancer and identifying neural stem cells
WO2007050380A3 (en) Tyrosine kinase inhibitors
WO2006078575A3 (en) Fluorinated aminoalkyl-4-oxo-3,4-dihydropyrido[3,4- d] pyrimidines as inhibitors of mitotic kinesins
ZA200809016B (en) 4, 5-Dihydro-[1,2,4] Triazolo [4,3-F] PteridinesS as protein kinase PLK1 inhibitors for the treatment of proliferative disorders
WO2007050383A3 (en) Tyrosine kinase inhibitors

Legal Events

Date Code Title Description
FA Abandonment or withdrawal